RadNet (RDNT)
(Delayed Data from NSDQ)
$62.30 USD
+1.96 (3.25%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $62.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.30 USD
+1.96 (3.25%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $62.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Zacks News
RadNet (RDNT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of 133.33% and 2.74%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Should Value Investors Buy RadNet (RDNT) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Value Medical Stocks to Buy for Safety Amid Market Volatility
by Indrajit Bandyopadhyay
We have narrowed our search to three value stocks from the Medical sector. These are PHG, RDNT and BVS.
Zacks Industry Outlook Highlights DaVita, Encompass Health, Option Care Health and RadNet
by Zacks Equity Research
DaVita, Encompass Health, Option Care Health and RadNet are part of the Zacks Industry Outlook article.
4 Stocks to Buy in a Booming Outpatient Home Health Industry
by Zacks Equity Research
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and RDNT are well-poised to gain.
Best Momentum Stocks to Buy for August 15th
by Zacks Equity Research
DFH, RDNT and PNNT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2023.
RadNet (RDNT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of 242.86% and 3.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 260% and 2.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
RadNet (RDNT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of -14.29% and 5.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
3 Medical Device Stocks With Potential to Fight Recession Risk
by Indrajit Bandyopadhyay
Increasing interest rates, higher costs and rising unemployment paint an unfavorable picture with the risk of a recession looming large. Here we discuss three medical stocks that may be good bets even in a recession.
Zacks Industry Outlook Highlights Chemed, Addus HomeCare, RadNet and The Pennant Group
by Zacks Equity Research
Chemed, Addus HomeCare, RadNet and The Pennant Group are part of the Zacks Industry Outlook article.
4 Promising Stocks From a Challenging Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. CHE, ADUS, RDNT and PNTG are well poised to gain from the prospects.
Why Fast-paced Mover RadNet (RDNT) Is a Great Choice for Value Investors
by Zacks Equity Research
RadNet (RDNT) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Are Investors Undervaluing RadNet (RDNT) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
RadNet (RDNT) Misses Q4 Earnings Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of -42.11% and 11.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
5 Toxic Stocks That Can Set Off Alarm Bells for Your Portfolio
by Rimmi Singhi
Investors who can correctly spot overpriced stocks and shun them at the right time can avoid big losses. Dump toxic stocks like MGM, ILMN, OMCL, HL and RDNT to prevent portfolio bleeding.
RadNet (RDNT) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of -43.75% and 0.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Elanco Animal Health Incorporated (ELAN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 25% and 0.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Encompass Health (EHC) Q3 Earnings Miss Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of -1.47% and 2.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is RadNet (RDNT) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
RadNet (RDNT) Stock Jumps 16%: Will It Continue to Soar?
by Zacks Equity Research
RadNet (RDNT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Quest Diagnostics (DGX) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
RadNet (RDNT) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of 200% and 1.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Chemed (CHE) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 1.26% and 1.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?